WuXiHybridTM is a world-class hybridoma platform with the most advanced, state-of-the-art technologies, enabling our clients for generating a wide variety of monoclonal antibodies to routine and challenging targets. Our cutting-edge innovations and well-experienced expert scientists have overcome key technical bottlenecks obstacles and delivered numerous high-quality therapeutic antibodies as well as key reagent antibodies to our customers all over the world.
Summarized advantages of WuXiHybridTM platform
- Potent immunization methods using various antigen formats
- High efficient cell fusion with optimized electrofusion technology
- High-throughput comprehensive screening strategy
- Semi-solid subcloning to assure hybridoma monoclonality
In the spirit of “striving for excellence”, our scientists will continuously make full use of the advantages of WuXiHybridTM technology platform to provide customers with the highest quality services, and continue to be the leading team in the field of hybridoma technologies.